Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 7/20 | 0.57 |
| ▸ | CES2 | O00748 | 3/20 | 0.35 |
| ▸ | CES1 | P23141 | 3/20 | 0.35 |
| ▸ | PRKDC | P78527 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6744464 | 1.00 | ERN1 (0.57) | ERN1CES2CES1PRKDCKDM4E | |
| SCHEMBL28892459 | 0.78 | ERN1 (0.50) | ERN1PRKDC | |
| SCHEMBL16830969 | 0.78 | ERN1 (0.44) | ERN1PRKDCKDM4EALDH1A1 | |
| SCHEMBL33526457 | 0.77 | ERN1 (0.38) | ERN1CES2CES1ESR1ESR2 | |
| SCHEMBL585592 | 0.76 | ERN1 (0.61) | ERN1CES2CES1KDM4EALDH1A1 | |
| SCHEMBL28848025 | 0.75 | ERN1 (0.41) | ERN1PRKDCKDM4EALDH1A1 | |
| SCHEMBL4501201 | 0.74 | ERN1 (0.39) | ERN1CES2CES1PRKDCKDM4E | |
| SCHEMBL919665 | 0.74 | KDM1A (0.42) | ERN1CES2CES1ALDH1A1 | |
| SCHEMBL31411394 | 0.74 | ERN1 (0.44) | ERN1PRKDCKDM4EALDH1A1 | |
| SCHEMBL24014278 | 0.73 | ERN1 (0.57) | ERN1CES2CES1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720055-A1 | CBL-B INHIBITORS AND METHODS OF USE THEREOF | Arcus Biosciences, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| EP-4688785-A1 | 5-AMINO-6, 8-DIHYDRO-1H-FURO [3, 4-D] PYRROLO [3, 2-B] PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS MTA-COOPERATIVE INHIBITORS OF PRMT5 | Beone Medicines I GmbH (CH) | 2026-02-11 | — | — | EP | disclosed |
| CN-115836076-B | Compounds as CAV1.2 activators | 诺华股份有限公司 | 2025-04-25 | — | — | CN | disclosed |
| WO-2025034858-A1 | FUSED PYRIDINES FOR THE TREATMENT OF CANCER AND OTHER INDICATIONS | THERAS, INC. (US) | 2025-02-13 | — | — | WO | disclosed |
| WO-2024243502-A1 | CBL-B INHIBITORS AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2024-11-28 | — | — | WO | disclosed |
| US-20240368177-A1 | 5-AMINO-6,8-DIHYDRO-1H-FURO[3,4-d]PYRROLO[3,2-b]PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS MTA-COOPERATIVE INHIBITORS OF PRMT5 | BEIGENE SWITZERLAND GMBH (CH) | 2024-11-07 | — | — | US | disclosed |
| WO-2024199255-A1 | 5-AMINO-6, 8-DIHYDRO-1H-FURO [3, 4-d] PYRROLO [3, 2-b] PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS MTA-COOPERATIVE INHIBITORS OF PRMT5 | BEIGENE SWITZERLAND GMBH (CH) | 2024-10-03 | — | — | WO | disclosed |
| CN-115698017-B | Methyl 2-methyl-5-oxo-1, 4,5, 7-tetrahydrofurano [3,4-b ] pyridine-3-carboxylate compounds as CAV1.2 activators | 诺华股份有限公司 | 2024-09-24 | — | — | CN | disclosed |
| CN-115232144-B | Nitrogen-containing condensed ring derivative, pharmaceutical composition, and preparation method and application thereof | 长春金赛药业有限责任公司 | 2024-04-02 | — | — | CN | disclosed |
| CN-114621135-B | LPA1 small molecule antagonist | 上海拓界生物医药科技有限公司 | 2024-01-30 | — | — | CN | disclosed |
| CN-115698017-A | Methyl 2-methyl-5-oxo-1, 4,5, 7-tetrahydrofuro [3,4-b ] pyridine-3-carboxylate compounds as CAV1.2 activators | 诺华股份有限公司 | 2023-02-03 | — | — | CN | disclosed |
| CN-114621135-A | LPA1 small molecule antagonist | 上海拓界生物医药科技有限公司 | 2022-06-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368177-A1 | 5-AMINO-6,8-DIHYDRO-1H-FURO[3,4-d]PYRROLO[3,2-b]PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS MTA-COOPERATIVE INHIBITORS OF PRMT5 | PRMT5, PRMT6, PRMT1 | ERN1 2579/4885CES2 4679/4885CES1 3811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.